Futures inch up; PCE data ahead; Trump unveils new tariffs - what’s moving markets

U.S. stock futures edged higher as markets await the critical August PCE inflation report, which will influence Federal Reserve rate decisions, though recent strong economic data has already tempered expectations for aggressive rate cuts. Concurrently, President Trump's announcement of new tariffs, including 100% duties on branded pharmaceuticals, and reports of potential U.S. policies to reduce reliance on semiconductor imports, have led to declines in global drugmaker and chipmaker stocks, highlighting escalating trade policy risks. Gold held steady amid safe-haven demand, while oil prices rose significantly on supply concerns.

Analysis

The market is exhibiting a cautious tone, with U.S. futures showing marginal gains ahead of the August personal consumption expenditures (PCE) price index release. While economists forecast a cooling in the core PCE to 0.2% month-on-month, recent robust economic data, including an upward revision to Q2 GDP and a decline in weekly jobless claims, has tempered expectations for aggressive Federal Reserve rate cuts. This has created policy uncertainty, with traders pricing an 88% chance of a 25-basis point cut in October but a less certain 62% probability for December. The primary source of negative pressure stems from escalating trade policy risks. President Trump's announcement of new tariffs, particularly a 100% duty on branded pharmaceuticals, has directly impacted non-U.S. drugmakers, causing shares of Novo Nordisk, Roche, and Novartis to decline. Concurrently, reports that the U.S. administration is considering measures to reduce reliance on semiconductor imports have pressured global chip stocks, including ASML, TSMC, and SK Hynix. This sentiment is also reflected in individual stock performance, as Jabil's shares fell despite a strong forecast, suggesting investor enthusiasm for AI-related hardware may be moderating, similar to the reaction seen with Micron.

Key Decisions for Investors

• Investors should urgently review exposure to non-U.S. pharmaceutical companies, as the newly announced 100% tariff on branded drugs introduces a significant and direct risk to their earnings and valuations.
• It is prudent to re-evaluate holdings in the global semiconductor supply chain, particularly in non-U.S. firms like ASML and TSM, given the potential for U.S. policies designed to favor domestic manufacturing.
• While the upcoming PCE data is important, investors should place greater weight on the next monthly jobs report, which is seen as more pivotal for influencing the Federal Reserve's rate decisions through year-end.
• The market's muted reaction to strong forecasts from Jabil and Micron signals a potential peak in AI hardware enthusiasm; therefore, apply heightened scrutiny to valuations in this sub-sector and avoid assuming all positive news will drive stock appreciation.